Home » BioCryst’s Hereditary Angioedema Candidate Misses Primary Endpoints
BioCryst’s Hereditary Angioedema Candidate Misses Primary Endpoints
BioCryst’s avoralstat failed to meet primary endpoints in the OPuS-2 trial for hereditary angioedema, according to the company.
The company said statistically significant improvements were observed in the higher 500-mg dose for secondary endpoints, which measured quality of life, attack duration and attack severity.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May